Estée Lauder Makes Strategic Investment in Clinical Skincare Pioneer, 111SKIN
In a significant move that highlights the merging of medical aesthetics and luxury beauty, The Estée Lauder Companies have announced a minority investment in 111SKIN. This London-based clinical skincare brand was established by renowned plastic surgeon, Dr. Yannis Alexandrides.
The investment, disclosed on April 29, 2026, emphasizes the beauty titan’s dedication to science-driven innovation. This comes as consumer demand increasingly veers towards high-performance, treatment-inspired skincare products. 111SKIN, founded in 2012, was initially created to expedite patients’ healing time post-cosmetic procedures.
At the core of the brand is its proprietary NAC Y2™ technology. This groundbreaking complex is designed to bolster skin repair and sustain a healthy, radiant, and resilient complexion. The brand boasts a portfolio of over 30 products, with formulations priced from $50 to $1,000.
“Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results,” stated Stéphane de La Faverie, President and CEO of The Estée Lauder Companies.
111SKIN operates via luxury retail channels including Harrods, Bluemercury, Nordstrom, and high-end spas such as Mandarin Oriental and Aman. The brand has a diversified global footprint, with North America accounting for approximately 40% of 2025 sales. Dr. Alexandrides will continue to spearhead the brand alongside its seasoned management team.
Source: Estée Lauder Companies Press Release